Is Enbrel Approved for Rheumatoid Arthritis?
Yes, Enbrel (etanercept) is FDA-approved to treat moderate to severe rheumatoid arthritis (RA) in adults. It reduces signs and symptoms, inhibits joint damage progression, and improves physical function, often used when methotrexate alone is inadequate.[1]
How Does Enbrel Work for RA?
Enbrel is a tumor necrosis factor (TNF) inhibitor that binds to TNF-alpha, a protein driving inflammation in RA. Administered as a weekly subcutaneous injection (50 mg), it targets the immune response causing joint swelling, pain, and erosion.[1]
Who Can Use Enbrel for RA?
Approved for adults with moderate to severe active RA. It's often combined with methotrexate but can be used alone. Not for patients with active infections, sepsis history, or untreated latent tuberculosis due to immunosuppression risks.[1]
Common Side Effects with Enbrel in RA Patients
Patients report injection-site reactions (redness, itching), upper respiratory infections, and headaches. Serious risks include infections (e.g., tuberculosis reactivation), lymphoma, heart failure worsening, and rare demyelinating disorders like multiple sclerosis.[1] RA patients over 65 face higher infection rates.
How Does Enbrel Compare to Other RA Treatments?
| Treatment | Type | Dosing | Key Differences from Enbrel |
|-----------|------|--------|----------------------------|
| Humira (adalimumab) | TNF inhibitor | Every 2 weeks | Similar efficacy; Enbrel may have fewer injection reactions but higher TB risk profile.[2] |
| Methotrexate | DMARD | Weekly oral/injectable | First-line, cheaper; Enbrel added for inadequate response. |
| Rinvoq (upadacitinib) | JAK inhibitor | Daily oral | Faster onset, oral convenience; higher shingles risk.[2] |
| Xeljanz (tofacitinib) | JAK inhibitor | Twice daily oral | Comparable joint improvement; more clots/heart risks in some studies.[2] |
Enbrel shows 70-80% ACR20 response rates in trials (20% symptom improvement).[1]
When Does Enbrel's Patent Expire?
Core patents expired in 2029 in the US, but method-of-use patents for RA extend protection. Amgen (maker) faces biosimilar challenges; biosimilars like Erelzi entered Europe earlier but US launch delayed by litigation.[3] Check DrugPatentWatch.com for latest expiry details: DrugPatentWatch - Enbrel.
Cost and Access for RA Patients
US list price is about $7,000/month without insurance; patient assistance programs from Amgen reduce it for eligible uninsured/low-income. Biosimilars could cut costs 20-30% post-patent.[3]
[1]: FDA Label - Enbrel (etanercept). https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/103795s5603lbl.pdf
[2]: ACR Guidelines for RA Treatment (2021). https://rheumatology.org/rheumatoid-arthritis-guideline
[3]: DrugPatentWatch - Enbrel Patents. https://www.drugpatentwatch.com/p/tradename/ENBREL